Safety and Efficacy of the Accent Magnetic Resonance Imaging™ (MRI) Pacemaker and Tendril MRI™ Lead

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
St. Jude Medical
ClinicalTrials.gov Identifier:
NCT01576016
First received: April 4, 2012
Last updated: March 17, 2014
Last verified: March 2014

April 4, 2012
March 17, 2014
March 2012
March 2014   (final data collection date for primary outcome measure)
  • Freedom from right atrial (RA) lead-related complications in the acute period [ Time Frame: Implant through 2 months ] [ Designated as safety issue: Yes ]
    Proportion of patients who do not have RA lead-related complications from implant through the 2 month study visit
  • Freedom from right ventricular (RV) lead-related complications in the acute time period [ Time Frame: Implant through 2 months ] [ Designated as safety issue: Yes ]
    Proportion of patients who do not have RV lead-related complications from implant through the 2 month study visit
  • Freedom from RA related complications in the chronic period [ Time Frame: 2 months thru 12 months ] [ Designated as safety issue: Yes ]
    Proportion of patients who do not have RA lead-related complications from the 2 month through the 12 month study visit
  • Freedom from right ventricular lead related complications in the chronic period [ Time Frame: 2 months thru 12 months ] [ Designated as safety issue: Yes ]
    Proportion of patients who do not have RV lead-related complications from the 2 month through the 12 month study visit
  • Freedom from MRI scan-related complications [ Time Frame: MRI Scan visit and 1 month after MRI scan visit ] [ Designated as safety issue: Yes ]
    Proportion of patients who do not have MRI-related complications from the MRI scan visit to the 1 month post MRI scan visit
  • Change in atrial capture thresholds (before and after the MRI Scan) [ Time Frame: MRI Scan visit and 1 month after MRI scan visit ] [ Designated as safety issue: No ]
    Difference in the proportion of patients with an increase in RA capture thresholds at 0.5 ms between those randomized to receive an MRI scan versus those not receiving an MRI scan.
  • Change in ventricular capture thresholds (before and after the MRI scan) [ Time Frame: MRI Scan visit and 1 month after MRI scan visit ] [ Designated as safety issue: No ]
    Difference in the proportion of patients with an increase in RV capture thresholds at 0.5 ms between those randomized to receive an MRI scan versus those not receiving an MRI scan.
  • Change in atrial sensing threshold (before and after the MRI scan) [ Time Frame: MRI Scan visit and 1 month after MRI scan visit ] [ Designated as safety issue: No ]
    Difference in the proportion of patients with an increase in RA sensing threshold between those randomized to receive an MRI scan versus those not receiving an MRI scan.
  • Change in ventricular sensing threshold (before and after the MRI scan) [ Time Frame: MRI Scan visit and 1 month after the MRI Scan visit ] [ Designated as safety issue: No ]
    Difference in the proportion of patients with an increase in RV sensing threshold between those randomized to receive an MRI scan versus those not receiving an MRI scan.
Not Provided
Complete list of historical versions of study NCT01576016 on ClinicalTrials.gov Archive Site
  • Freedom from system-related complications [ Time Frame: Implant through 12 months ] [ Designated as safety issue: Yes ]
    Proportion of patients who do not have system-related complications from implant through the 12 month study visit
  • Atrial capture threshold at the MRI visit [ Time Frame: MRI Scan visit (approx 3 months post implant) ] [ Designated as safety issue: No ]
    Proportion of patients with RA capture threshold ≤2.0V at the MRI visit
  • Ventricular capture threshold at the MRI visit [ Time Frame: MRI Scan visit (approx 3 months post implant) ] [ Designated as safety issue: No ]
    Proportion of patients with RV capture threshold ≤2.0V at the MRI visit
Not Provided
Not Provided
Not Provided
 
Safety and Efficacy of the Accent Magnetic Resonance Imaging™ (MRI) Pacemaker and Tendril MRI™ Lead
Accent Magnetic Resonance Imaging Pacemaker and Tendril Magnetic Resonance Imaging™ Lead Investigational Device Exemption Study

The MRI Study is a prospective, multi-center, clinical study designed to evaluate the safety and efficacy of the Accent MRI System in a patient population indicated for implant of a pacemaker within and outside of the MRI environment.

The safety and efficacy of the Accent MRI pacemaker and Tendril MRI lead will be evaluated as described below:

Lead Safety Safety of the Tendril MRI™ lead will be evaluated in terms of freedom from RA and RV lead-related complications at implant to 2 months, and at the 2 through the 12 month visit.

MRI Safety The safety of the Accent MRI system will be evaluated in terms of freedom from MRI scan related complications in the month following the MRI scan.

Lead Efficacy Efficacy of the Tendril MRI™ lead will be evaluated in terms of the change in atrial and ventricular capture and sensing thresholds before and after the MRI scan.

Secondary Endpoints Safety Safety of the Accent MRITM system will be evaluated in terms of freedom from system-related complications through the 12 month visit.

Efficacy Efficacy of the Tendril MRI™ lead will be evaluated in terms of the atrial and ventricular capture thresholds at the MRI Visit.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Adverse Effect of MRI on an Implanted Pacemaker Lead
  • Adverse Effect of MRI on an Implanted Pacemaker
  • Device: Accent MRI system
    Patients implanted with an Accent MRI system will receive 30 minutes of magnetic scan imaging
    Other Names:
    • Accent MRI pacemaker
    • Tendril MRI lead
  • Device: Accent MRI system
    Patients implanted with an Accent MRI system will wait for one hour without receiving an MRI scan
    Other Names:
    • Accent MRI pacemaker
    • Tendril MRI lead
  • Active Comparator: Accent MRI system MRI Scan Group
    Patient implanted with an Accent MRI system will receive an MRI scan
    Intervention: Device: Accent MRI system
  • Placebo Comparator: Accent MRI System MRI Control Group
    Patient implanted with an Accent MRI system will not receive an MRI scan
    Intervention: Device: Accent MRI system
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
800
December 2014
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

Eligible patients will meet all of the following:

  1. Have an approved indication per ACC/AHA/HRS guidelines for implantation of a pacemaker
  2. Will receive a new pacemaker and lead
  3. Be willing to undergo an elective MRI scan without sedation
  4. Be able to provide informed consent for study participation (legal guardian is NOT acceptable)
  5. Be willing and able to comply with the prescribed follow-up tests and schedule of evaluations
  6. Is not contraindicated for an MRI scan (per the pre-MRI safety screening form)

Exclusion Criteria:

Patients will be excluded if they meet any of the following:

  1. Are medically indicated for an MRI scan at the time of enrollment
  2. Have an existing pacemaker or ICD. A new pacemaker and lead is required for enrollment
  3. Have an existing active/inactive implanted medical device, e.g., neurostimulator, infusion pump, etc.
  4. Have a non-MRI compatible device or material implanted (e.g., intracranial aneurysm clip, non-MRI compatible devices or material, metals or alloys, etc.)
  5. Have a lead extender or adaptor
  6. Be unable to fit in MRI bore; will come into contact with the magnet façade inside the MRI bore.
  7. Have a prosthetic tricuspid heart valve
  8. Are currently participating in a clinical investigation that includes an active treatment arm
  9. Are allergic to dexamethasone sodium phosphate (DSP)
  10. Are pregnant or planning to become pregnant during the duration of the study
  11. Have a life expectancy of less than 12 months due to any condition
  12. Patients with exclusion criteria required by local law (e.g., age)
  13. Are unable to comply with the follow up schedule
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Belgium,   Finland,   Netherlands
 
NCT01576016
60028820
No
St. Jude Medical
St. Jude Medical
Not Provided
Study Director: Ashish Oza St. Jude Medical
St. Jude Medical
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP